Testing JUR-003, a New Treatment, in Adults With Metastatic Prostate Cancer
Tests the safety of JUR-003 in adults with metastatic prostate cancer.
Key facts
- Who runs it
- Juri Biosciences, Inc.
- Where
- Grand Rapids, Lake Success, Nashville, and San Antonio, United StatesSee the 4 sites
- Trial code
- Registry title
- JUR-003 in Adult Patients With Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 210 people, planned
- Started
- 26 Oct 2026
- Expected to end
- Jun 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- JUR-003
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult men with prostate cancer that has spread. It tests a new drug, JUR-003, for the first time in people.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Adenocarcinoma of the prostate, confirmed by tissue or cell tests. The disease must be measurable or evaluable on scans. One expansion group also needs PSMA-avid disease on PSMA-PET and PSA of 0.2 ng/mL or higher after earlier treatment.
- Biomarker or test result
- For one expansion group only (Part 2.1B): PSMA-avid disease on PSMA-PET, with uptake above blood pool (PSMA score ≥1).
Main reasons for not taking part
- Immunodeficiency, or a known HIV infection
- Earlier stem cell, bone marrow or organ transplant
- Active or chronic hepatitis B or hepatitis C infection
- Active autoimmune disease that needed systemic treatment in the past 2 years
- Active cancer spread to the brain or its lining, or untreated spinal cord compression
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Must be ≥18 years of age at the time the informed consent form (ICF) is signed
- Has a histologically or cytologically confirmed adenocarcinoma of the prostate
- Has either of the following:; Measurable disease per RECIST v1.1 (with PCWG3 modifications); Evaluable disease per PCWG4, as assessed by the local site Investigator/radiology; For Part 2.1B (omPC expansion) only: PSMA-avid disease on PSMA-PET, defined as lesion(s) demonstrating uptake above blood pool (PSMA score ≥1) and assessed by the Investigator as consistent with metastatic prostate cancer, in the setting of biochemical recurrence (PSA ≥0.2 ng/mL)
Who cannot take part
- Has had a prior stem cell, bone marrow, or organ transplant
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Individuals with previously treated CNS metastases may participate in JUR-003 monotherapy cohorts (Parts 1.1, 2.1, and 1.3 where applicable) provided they are radiologically stable (ie, without evidence of progression for at least 2 weeks by repeat imaging [note that the repeat imaging should be performed during study Screening]), clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study drug
- Has untreated spinal cord compression. Individuals must be neurologically stable off steroids for at least 4 weeks prior to first dose of study drug
- Has a history of a previous secondary malignancy within 3 years of Screening (except basal cell or squamous cell carcinoma of the skin or carcinoma in situ treated with curative therapy or other localized, low-grade tumors deemed cured, or whose natural history does not have the potential to interfere with the safety or efficacy assessments of the current study and not treated with systemic anticancer therapy [except hormonal therapy])
- Has a history of venous thromboembolic events (eg, pulmonary embolism) within 1 month prior to the first dose of JUR-003. Uncomplicated (Grade ≤2) deep vein thrombosis is not considered exclusionary
- Has a known history of human immunodeficiency virus (HIV) infection
- Has active or chronic hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
- Has an active autoimmune disease (non-immunotherapy induced conditions) that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)
- Has a history of (noninfectious) pneumonitis that required steroids or current active organizing pneumonitis/interstitial lung disease
- Has a known psychiatric or substance abuse disorder that would interfere with the individuals' ability to cooperate with the requirements of the study
- Has a diagnosis of immunodeficiency
Where in United States
- START | MidwestGrand Rapids, United StatesContact: Lisa KnappTaking people
- START New YorkLake Success, United StatesContact: Lisa KnappTaking people
- SCRI Oncology PartnersNashville, United StatesContact: Lisa KnappTaking people
- START | San AntonioSan Antonio, United StatesContact: Lisa KnappTaking people
About the trial
What the trial wants to find out
JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer. This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.
The 2 groups in the trial
- Part 1 (Dose Escalation)Treatment being tested
Participants will receive JUR-003 to determine the recommended dose for expansion (RDE) regimen.
Treatment: JUR-003
- Part 2 (Dose Expansion)Treatment being tested
Participants will receive JUR-003 at the RDE as determined in Part 1 of the study to confirm the safety and anti-tumor activity.
Treatment: JUR-003
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of JUR-003 in Adult Patients With Metastatic Prostate Cancer
- Plain-language title
- Testing JUR-003, a New Treatment, in Adults With Metastatic Prostate CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026